RWE vs. Clinical Trials
Thursdays
RWE vs. Clinical Trials: What Each Can (and Can’t) Tell Us
When people talk about medical evidence, the conversation often turns into a false choice: real-world evidence or clinical trials. Which is better? Which is more credible? Which should decision-makers trust?
The truth is simpler and far more useful:
Real-world evidence (RWE) and clinical trials answer different questions. Understanding what each can and can’t tell us is essential for anyone involved in healthcare decision-making, from researchers and clinicians to payers, regulators, and policy leaders.
What Clinical Trials Are Designed to Tell Us
Randomized controlled trials (RCTs) are designed to answer a very specific question:
Does this intervention work under ideal, controlled conditions?
By using randomization, strict inclusion and exclusion criteria, and controlled protocols, trials are optimized to establish internal validity, confidence that observed outcomes are caused by the intervention itself.
What Clinical Trials Do Well
Clinical trials excel at:
Establishing efficacy and safety
Minimizing bias and confounding
Supporting regulatory approval
Demonstrating causal relationships
Because of this rigor, RCTs remain the foundation for initial drug approval and guideline development.
What Clinical Trials Can’t Fully Tell Us
However, that same rigor comes with trade-offs. Clinical trials often struggle to answer questions such as:
How does this treatment perform in routine clinical practice?
What happens when patients have multiple comorbidities?
How do adherence, persistence, and real-world dosing affect outcomes?
How does this therapy compare to alternatives not included in the trial?
What is the long-term economic and quality-of-life impact?
In short, trials tell us what can happen but not always what does happen.
What Real-World Evidence Is Designed to Tell Us
Real-world evidence is generated from data collected outside the controlled trial setting, including:
Claims and billing data
Electronic health records (EHRs)
Disease registries
Patient-reported outcomes
Pragmatic and observational studies
RWE asks a different question:
How does this intervention perform in real life, across real patients and healthcare systems?
What RWE Does Well
When designed appropriately, RWE is particularly strong at:
Assessing effectiveness in routine care
Capturing outcomes in broader, more diverse populations
Evaluating treatment patterns, adherence, and persistence
Comparing therapies in real-world settings
Measuring healthcare utilization and costs
Identifying unmet needs and care gaps
RWE brings context, scale, and relevance. Elements that are critical for payer decision-making, population health management, and post-marketing strategy.
What RWE Can’t Fully Tell Us
RWE also has limitations that must be acknowledged:
Greater susceptibility to bias and confounding
Data quality and completeness issues
Limited control over exposure and outcome measurement
Challenges in establishing causality
Without thoughtful study design and analytic rigor, RWE can mislead rather than inform.
Why the Debate Misses the Point
Framing RWE and clinical trials as competitors misses their true value. In reality, they are complementary tools within a broader evidence ecosystem.
Clinical trials establish whether a therapy works
RWE shows how it works in practice
Together, they provide a more complete understanding of:
Clinical benefit
Patient experience
Economic value
Equity and access
This integrated view is increasingly essential as healthcare shifts toward value-based care and accountability.
How Decision-Makers Use Both
Today, regulators, payers, and health systems rarely rely on a single evidence source.
Regulators may use RWE to support post-marketing commitments, safety monitoring, and label expansions
Payers rely on RWE to assess comparative effectiveness and budget impact
Clinicians look to RWE to understand how therapies perform in patients who look like their own
Health systems use RWE to guide quality improvement and population health initiatives
Each stakeholder benefits most when trial data and RWE are aligned.
Choosing the Right Evidence for the Right Question
The most important question is not which evidence type is better, but rather:
What decision are we trying to inform?
Regulatory approval? → Clinical trials
Coverage and reimbursement? → RWE + trials
Comparative effectiveness? → RWE
Long-term safety and utilization? → RWE
Mechanism and causality? → Clinical trials
High-quality evidence strategy starts with clarity of purpose.
Final Takeaway
Clinical trials and real-world evidence are not rivals. They are partners.
In a healthcare system that must balance innovation, access, cost, and equity, relying on one without the other leaves critical gaps. When integrated thoughtfully, RWE and clinical trials together provide the insight needed to make informed, patient-centered, and value-driven decisions.
Let’s Keep the Conversation Going
As the evidence ecosystem continues to evolve, the most meaningful insights come from understanding how clinical trials and real‑world evidence work together. If you’re thinking about how to balance these evidence types, strengthen your organization’s RWE strategy, or better align evidence generation with payer and regulatory expectations, I’d love to hear what questions you’re exploring. Your perspective adds depth to this conversation, and I’m always eager to connect with others committed to building smarter, more patient‑centered decision-making in healthcare.